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ABSTRACT
Background: In Japan, oral antihistamines are frequently used as the initial treatment for seasonal allergic
rhinitis (SAR), and intranasal steroids are added when nasal symptoms worsen. This study aimed to evaluate
whether starting treatment with fluticasone propionate nasal spray (FP) from the beginning of pollinosis symp-
toms and adding fexofenadine hydrochloride tablet (FEX) when SAR is aggravated could achieve improved
amelioration of nasal symptoms throughout the pollen season in comparison with a treatment that involves
starting with FEX and later adding FP.
Methods: In this pragmatic, randomized, open-label, parallel-group trial, 51 Japanese cedar pollinosis patients
(age, 16-85 years) were randomly divided and administered FP 100 mcg twice daily as an initial drug with FEX
60 mg twice daily as an additional drug and the same treatment in the reverse order. Nasal symptoms were
evaluated in a daily dairy using a 4-point scale. The primary outcome was area under curve of the line repre-
senting the daily total nasal symptom score in the pollen season on a graph.
Results: Initial treatment with FP was significantly (P = 0.0015) more effective than initial treatment with FEX
in improving the primary outcome. The average daily total nasal symptom score in the initial treatment with FP
group was better than that in the initial treatment with FEX group throughout the pollen season.
Conclusions: Initiating treatment with FP and adding FEX might lead to improved outcomes for nasal symp-
toms in comparison with the same drugs administered in the reverse order.
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INTRODUCTION
Allergic rhinitis (AR) is a common disease affecting
over 500 million people worldwide.1 AR is an IgE-
mediated inflammation after allergen exposure to the
nasal membrane and is characterized by four bother-
some symptoms of runny nose, stuffy nose, itchy
nose, and sneezing. AR influences the quality of life of
the patient through impairment of daily activities, so-
cial function, emotions, and sleep patterns, although
it is not a life-threatening disease.2-5 Moreover, AR is
a social burden in terms of medical expenditure. In
the USA, the direct cost of this disease was estimated
to be between $2 and $5 billion in 2003.6
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Cedar pollen is the most common outdoor allergen
in Japan; it disperses in February and March every
year. Epidemiological studies have demonstrated that
the prevalence of seasonal allergic rhinitis (SAR) due
to this pollen has risen from 16% in 1998 to 26% in
2008.7
Practical Guideline for the Management of Allergic
Rhinitis in Japan recommends that clinicians treat
SAR patients from the beginning of early symptoms,
immediately after the start of pollen dispersal.7,8 Ac-
cording to this recommendation, if the initial treat-
ment fails to control the symptoms, additional medi-
cation is considered necessary. Oral antihistamines
are considered the most frequently used drugs for
the initial treatment of SAR in Japan,9 and intranasal
steroids are added for ameliorating the subsequent
aggravation of nasal symptoms with increasing pollen
dispersal as the season progresses. However, al-
though certain studies have revealed that intranasal
steroids have stronger effects on allergic rhinitis as
compared to oral antihistamines,10 the positioning of
the two drugs in the initial and additional treatments
remains unclear. We hypothesized that improved
amelioration of nasal symptoms could be achieved
throughout the pollen season by initiating treatment
with an intranasal steroid followed by an oral antihis-
tamine as a backup drug in comparison with the
same treatment in the reverse order.
Fluticasone propionate aqueous nasal spray (FP) is
an intranasal steroid commonly used for treating al-
lergic rhinitis in adults and children.11,12 It has been
shown that FP is effective for improving both nasal
and ocular symptoms associated with SAR.13,14 Local
adverse effects of FP, such as epistaxis and nasal dry-
ness, are generally mild and temporal. Moreover, the
low bioavailability of this drug is considered to be as-
sociated with fewer systemic adverse effects in cases
of prolonged use.15-17
Fexofenadine hydrochloride tablet (FEX) is the ac-
tive metabolite of terfenadine.18 Certain clinical stud-
ies have demonstrated FEX to favorably influence na-
sal symptoms and the resultant quality of life.19-21
FEX causes minimal sedation and does not interfere
with concentration-intensive activities such as driv-
ing.22 Moreover, FEX is considered a safe drug in
view of cardiac toxicity.23
Our study aimed to evaluate whether initial treat-
ment with FP followed by FEX as the additional treat-
ment would lead to improved amelioration of the na-
sal symptoms of cedar pollinosis as compared to the
same drugs administered in the reverse order.
METHODS
STUDY DESIGN
A pragmatic randomized, open-label, parallel-group
study design was used. The target population of this
study was asymptomatic AR patients or those with
mild symptoms visiting a medical institute early in
the cedar pollen season. This study was conducted at
seven private ENT clinics and the ENT outpatient de-
partment of a general hospital in Yamanashi Prefec-
ture, Japan, from January 1 to March 31, 2007.
POLLEN COUNTS
Cedar pollen grains were collected and measured by
using a Durham sampler daily from January 1, 2007
at the University of Yamanashi Hospital. Pollen
counts were expressed as a mean of grain per square
centimeter. We defined “early cedar pollen season”
as the period between the first day of identifying a ce-
dar pollen grain and the second day of two consecu-
tive days of identifying cedar pollen grains 1 grain
cm2 for the first time in the season. “Full pollen sea-
son” was defined as the period between the end of
the early pollen season until March 25.
PARTICIPANTS
The participants were recruited through physician re-
ferrals when patients visited a medical institute early
in the pollen season. The following 4 inclusion crite-
ria were considered: (1) age 16 years, (2) a history
of Japanese cedar pollinosis for at least 2 seasons be-
fore study entry, (3) a positive allergy skin test to
Japanese cedar pollen or Japanese cedar pollen-
specific IgE RAST score class 2, and (4) asympto-
matic or mild symptoms (daily total nasal symptom
score 2). Written informed consent was also neces-
sary for participation in this study.
Patients were excluded if (1) they had taken any
anti-allergy drugs at the beginning of the study; (2)
had any other nasalparanasal sinus disease, pharyn-
gitis, laryngitis, respiratory tract infection, or asthma;
(3) had a history of glaucoma, gastric ulcer, uncon-
trollable hypertensiondiabetes, hepatitis, or malig-
nant tumor; (4) were in a build-up phase of specific
immunotherapy to Japanese cedar pollen; (5) had a
history of nasalparanasal sinus surgery; (6) had a
history of hypersensitivity to fluticasone propionate
or fexofenadine hydrochloride; and (7) were preg-
nant or lactating.
The physician contacted the data-collecting center
after evaluating the eligibility criteria of the patient.
Patients who matched the eligibility criteria were reg-
istered in the study and assigned in accordance with
the computer-generated random allocation table with
a block size of 4 and 6. To conceal the assignment se-
quence, central randomization was used, and the
block size was not released.
INTERVENTIONS
FP group intervention: One fluticasone 50 μg per nos-
tril twice a day (total 200 μgday) was administered
from the beginning of pollinosis symptoms as the in-
itial drug. Sixty mg of fexofenadine orally twice a day
(total 120 mgday) was started as an additional drug
for treating the exacerbation of nasal symptoms. Ex-
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Fig.　1　Schematic summary of the fl ow of participants in the study.
Assessed for Eligibility: 52
Not meeting criteria: 1
FEX group: 26
Lost to Follow up: 1 (Lost diary)
Randomly Assigned: 51
FP group: 25
Lost to Follow up: 1 (Lost diary)
Analyzed: 25 Analyzed: 26
Table　1　Participants characteristics
FP group
(n = 25)
FEX group
(n = 26)
Age, years   39 (29, 45)   43 (31, 53)
Male/Female, n 10/15 7/19
Age of JCP onset, years   20 (15, 32)   20 (16, 38)
JCP in 2006, n
Severity
none 0 1
mild 16 18
moderate 5 2
severe 0 1
unknown 4 4
Treatment
OAH 7 9
INS 3 2
OAH + INS 3 4
unknown 5 3
no treatment 7 8
Immunotherapy, n 1 0
Overall RQLQ score 0.38 (0.00, 0.78) 0.47 (0.18,1.22)
Date of registration 1/31 (1/25, 2/2) 1/30 (1/27, 2/1)
Median (25 percentile, 75 percentile).
FP, fl uticasone propionate nasal spray; FEX, fexofenadine hy-
drochloride tablet; JCP, Japanese cedar pollinosis; OAH, Oral anti-
histamines; INS, Intranasal steroids.
acerbation was defined as a daily total nasal symptom
score of 4 more for 4 times a week.
FEX group intervention: Oral fexofenadine 60 mg
twice a day (total 120 mgday) was administered
from the beginning of pollinosis symptoms as the in-
itial drug. One fluticasone 50-μg puff per nostril twice
a day (total 200 μgday) was started as the additional
drug for treating the exacerbation of nasal symptoms
as mentioned above.
Sodium cromoglicate 2% eye drops were given for
administration on an as-needed basis to alleviate ocu-
lar symptoms to both patient groups.
OUTCOMES MEASURED
Participants assessed 4 nasal symptoms, i.e., runny
nose, stuffy nose, sneezing, and itchy nose, and 3
ocular symptoms-tearing, redness, and itchy eyes on
the basis of a 4-point scale in a daily dairy during the
study as follows: 0, no symptom evident; 1, symptom
present but not bothersome; 2, definite symptom that
is bothersome but tolerable; and 3, symptom that is
hard to tolerate. Participants also filled a Japanese
version of the rhinoconjunctivitis quality of life ques-
tionnaire (RQLQ) every time when they visited the
medical institute.
The primary outcome was the area under the curve
(AUC) of the line representing the total nasal symp-
tom score (TNSS) in the full pollen season on a
graph. Secondary outcomes were AUC of the 4 nasal
and total ocular symptom scores in full pollen season
on a graph and the change in the overall and 7 do-
main scores of RQLQ at the peak of the pollen season
from the time of registration in the study (i.e., base-
line).
The drug dosage for each participant was also
noted from their daily dairy. Adverse events were
also recorded from the daily dairy and from clinical
examination records.
SAMPLE SIZE
The clinically significant difference for daily TNSS
was determined to be 0.5 in late February, 0.75 in
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Fig.　2　Average daily total nasal symptom score and pollen counts during the study period. Par-
ticipants were registered and randomly assigned to fl uticasone propionate nasal spray (FP) and 
fexofenadine hydrochloride tablet (FEX) groups between January 19 and February 9, 2007. In 
both the groups, the peak of the average daily total nasal symptom score (TNSS) was recognized 
in early March.
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early March, and 1.0 in late March. Assuming the
least expected difference in the AUC of TNSS be-
tween the two groups to be 26 and a standard devia-
tion of 50 as derived in our previous study,24 a two-
sided alpha of 0.05, and power of 0.8 with equal allo-
cation, the estimated sample size needed to be 52 in
each group. Taking into account a 20% dropout rate,
we needed 120 participants in total.
STATISTICAL METHODS
We compared the two groups in terms of the AUC of
the symptom scores and the change in RQLQ scores
by Wilcoxon’s rank-sum test. These analyses were
based on intent-to-treat. Missing data of daily symp-
tom scores were predicted to be caused as the result
of participants dropping out or insufficient measure-
ment. Therefore, we utilized an imputation method
for determining the missing data in the trial protocol.
In brief, the missing data could be replaced by the
mean of the available data of the participant’s as-
signed treatment group from the first day of the full
pollen season to the day of the maximum pollen dis-
persal and by the last observational data noted by the
subject from the day following the maximum pollen
dispersal until March 25. The clinical characteristics
of the participants and the drug dosage were summa-
rized as representative values for each group.
The statistical software package used to analyze
the data was Stata Software version 11 (Stata Corpo-
ration, College Station, Texas, USA).
INSTITUTIONAL REVIEW BOARD AND CLINICAL
TRIAL REGISTRATION
The Institutional Review Board of the Faculty of
Medicine, University of Yamanashi, had approved the
protocol of this study in December 2006. The clinical
trial registration number is UMIN000000575 (www.
umin.ac.jpctrindexhtm).
RESULTS
The period of the enrollment and random assignment
was from January 19 to February 9, 2007 in accor-
dance with pollen count as measured by the Durham
sampler. We followed up the participants until the last
week of March 2007.
Fifty-one participants were randomly assigned to
either the FP group or the FEX group. We could not
collect the diary of one participant from each group
(Fig. 1). Baseline clinical characteristics of both the
treatment groups are shown in Table 1. These groups
were comparable with respect to their demographic
background. Medication use for cedar pollinosis in
the 2006 season was almost identical in both the
groups.
Stepwise Treatment for Seasonal Allergic Rhinitis
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Fig.　3　The area under the curve (AUC) for each symptom score during full pollen season. Median symptom 
scores are indicated with horizontal bars. The vertical bars indicate the range from lower to upper adjacent val-
ues, and the horizontal boundaries of the boxes represent the 25% and 75% percentile. Full pollen season was 
between February 10 and March 25, 2007. *P < 0.05. **P < 0.01. P values (2-sided) are derived from Wilcoxon’s 
rank-sum test for group comparisons.
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Pollen counts and average daily TNSS of the treat-
ment groups are shown in Figure 2. The average
daily TNSS of the FP group was lower than the score
of the FEX group throughout full pollen season.
The area under the TNSS curve for the FP group
(median = 45; interquartile range = 25 to 75) was
significantly lower than that for the FEX group (me-
dian = 109; interquartile range = 75 to 158; P =
0.0015). For the 4 nasal symptoms, i.e., runny nose,
stuffy nose, sneezing, and itchy nose, the AUC for the
FP group was significantly lower than that for the
FEX group (P = 0.0008, 0.0175, 0.0128, and 0.0166, re-
spectively) (Fig. 3). No significant difference was
noted for the area under the TOSS curve between the
two groups (P = 0.8358).
We did not observe any significant differences be-
tween the two treatment groups in the degree of
change in the overall RQLQ score at the peak of the
pollen season from baseline (FP: median = 0.13; inter-
quartile range = 0.02 to 1.06; FEX: median = 0.44; in-
terquartile range = -0.16 to 1.21; P = 0.3946). No sig-
nificant difference was recognized between the two
groups in the analyses of the 7 domain scores for
RQLQ (data not shown).
Throughout the study, 67% of the FP group (n =
16) and 40% of the FEX group (n = 10) used only the
initial drug. The backup drug was taken by 33% (n =
8) and 60% (n = 15) of the FP and FEX groups, re-
spectively. The timing of starting the backup drug
was also different between the two groups. Partici-
pants who started the backup drug at earlier timing
than instructed were 25% of the FP group (n = 6) and
8% of the FEX group (n = 2). Though 4 participants of
the FP group and 16 of the FEX group met the re-
quirement of starting the backup drug, 2 (50%) of the
4 of FP group and 12 (75%) of the 16 of the FEX
group were late to start the backup drug or did not
use the backup drug. The use of sodium cromogli-
cate eye drops was similar in both the groups (Table
2).
Nasal bleeding was the most frequently reported
adverse effect by 4 (16%) of the 25 participants from
the FP group; none of the FEX group participants re-
ported the same. No adverse events leading to the
discontinuation of the treatment were observed.
DISCUSSION
Our study evaluated the difference in the outcomes
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Table　2　Medications used in this trial
FP group
(n = 24)
FEX group
(n = 25)
Date of starting drug therapy  2/2 (1/31, 2/7)  2/1 (1/30, 2/2)
Number of participants using drugs, n (%)
FP only  16 (67)   0 (0)
FEX only   0 (0)  10 (40)
FP + FEX   8 (33)  15 (60)
Number of doses
FP† 100 (91, 105)  11 (0, 50)
FEX‡   0 (0, 8) 101 (95, 108)
SCED§  20 (1,78)  28 (0, 72)
Timing of additional drug, n (%)
Not requiring additional drug with the low tnss  14 (58)   7 (28)
Not using additional drug despite the rise of tnss   2 (8)   3 (12)
Starting additional drug at later timing than instructed   0 (0)   9 (36)
Starting additional drug as instructed   2 (8)   4 (16)
Starting additional drug at earlier timing than instructed   6 (25)   2 (8)
Median (25 percentile, 75 percentile).
FP, fl uticasone propionate nasal spray; FEX, fexofenadine hydrochroride tablet; SCED, Sodium cromoglicate eye drop; tnss, total nasal 
symptom score.
†One fl uticasone puff per nostril twice a day was counted as two times.
‡Intake of fexofenadine hydrochroride tablets was counted.
§Number of ocular instillation was counted.
for nasal symptoms of cedar pollinosis in a Japanese
population depending on the order of drugs (FP and
FEX) used as the initial and additional treatment for
SAR.
In the primary outcome, we noted the area under
the TNSS curve for the FP group to be significantly
lower than that for the FEX group. Moreover, the
curve for the FP group tended to be lower than that
for the FEX group throughout the pollen season. We
therefore considered that first-line treatment with FP,
backed up by FEX, would be more effective for treat-
ing the nasal symptoms of seasonal allergic rhinitis as
compared to the reverse order of the same drugs
from the beginning of the pollen season to its end.
In the secondary outcomes, the AUC for each of
the 4 nasal symptom scores for the FP group was sig-
nificantly lower than that for the FEX group. This
finding supported our abovementioned recommenda-
tion derived from the primary outcome. However, no
significant differences were noted in the area under
the TOSS curve and the RQLQ scores between the
two treatment groups.
In the medication usage, participants who used
only the initial drug were 67% of the FP group and
40% of the FEX group. In terms of medication cost,
starting treatment for mild AR with FP and backed up
by FEX in the case of AR aggravation might be better
than treatment with the same drugs in the reverse or-
der.
The timing of using the backup drug is also impor-
tant point to generalize the results of this pragmatic
trail into clinical practice. Participants starting the
backup drug at earlier timing than instructed were
25% in the FP group and 8% in the FEX group. Propor-
tion of the participants starting the backup drug at
later timing than instructed or using no backup drugs
in the population who needed backup drug were 50%
in the FP group and 75% in the FEX group. These
data may reflect that Japanese cedar pollinosis pa-
tients prefer anti-histamine tablets as an additional
drug rather than intranasal steroids.
The following reasons may account for our results
of primary endpoint from this trial. First, starting
treatment with FP may be more effective as com-
pared to FEX against minimal persistent inflamma-
tion with low pollen counts.25 Second, backup therapy
with FP nasal spray may not be entirely effective be-
cause of ineffective nasal diffusion caused by inferior
turbinate swelling with the progress of the pollen sea-
son. Third, the backup drug was used early in the FP
group as compare to the FEX group.
Studies regarding the stepwise treatment of SAR
are few. Juniper and colleagues conducted a random-
ized clinical trial for seasonal ragweed rhinoconjunc-
tivitis comparing initial treatment with FP backed up
by terfenadine and initial treatment with terfenadine
backed up by FP,26 wherein participants were advised
to start their medication either before pollen was ex-
pected in the air or immediately after experiencing
their first symptoms, with RQLQ scores being the pri-
mary outcome. They concluded that there was little
difference in the therapeutic benefit between the two
Stepwise Treatment for Seasonal Allergic Rhinitis
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approaches, as the difference in the overall RQLQ
score between the two groups was on the borderline
of statistical significance with the mean difference in
RQLQ scores not being clinically important. Simi-
larly, we did not note a statistically significant differ-
ence in the RQLQ scores between the FP and FEX
groups. However, this may have been due to the lack
of statistical power for detecting differences in the
RQLQ scores between the two groups with small
sample sizes.
The control of ocular symptoms is an important
point in treating pollinosis. Bernstein and colleagues
showed that FP reduced ocular symptoms more than
or equal to the effect of loratadine tablets in the treat-
ment of SAR.14 We noted no differences between the
two intervention groups for either TOSS or the usage
of sodium cromoglicate eye drops, suggesting that
FP had an ameliorating effect on ocular symptoms
comparable to that of FEX.
Our study has certain limitations. The small sample
size may have decreased the statistical power. How-
ever, we successfully determined a statistically sig-
nificant difference between the two intervention
groups in the AUC of TNSS, i.e., the primary out-
come. This was possible because the therapeutic ef-
fect of the initial treatment with FP and additional
FEX on the primary outcome was greater than that
assumed before starting this trial. Further, as our
study did not involve placebo controls, a bias in each
participant’s memory regarding the effect of previous
SAR medication, including FP and FEX, may have af-
fected the daily symptom scores. However, no defi-
nite difference was noted for SAR medication in the
2006 season between the two groups. We therefore
considered that such a bias would have little impact
on the results. Additionally, our study did not involve
any blinding processes, which may have led to a po-
tential bias in the results. To resolve these limita-
tions, a larger randomized controlled trial would be
necessary in the future to further elucidate our re-
sults.
In conclusion, we consider that initiating treatment
with FP and adding FEX might lead to improved out-
comes for nasal symptoms in comparison with the
same drugs administered in the reverse order.
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